Big pharmas will ask themselves these questions ... Big pharmas will ask themselves these questions:
- Will urologists be interested by this treatment?
- What kind of revenues can this treatment get me?
- Can I add something (more doses, higher doses, combo, etc ...) to this treatment that could increase those initial revenues?
___________________________
ScienceFirst - (4/27/2023 10:42:27 AM) The FDA will grant us Breakthrough based on these questions It all comes back to these questions? - Does this treatment give more options to patients, for them to spare their bladder? - Does the FDA have the luxury, yet, serious arguments, to not make this treatment available to patients? - Does this treatment deliver higher efficacy results than competition? - Does this treatment offer high safety profile? - Does this treatment achieve its primary, secondary and tertiary endpoints?